Group One Trading
TVTX icon

Group One Trading’s Travere Therapeutics TVTX Stock Holding History

Group One Trading’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$948K Sell
31,900
-9,800
-24% -$293K ﹤0.01% 2778
2025
Q4 		$1.59M Buy
41,700
+2,800
+7% +$91K ﹤0.01% 2476
2025
Q3 		$930K Hold
38,900
– – ﹤0.01% 3112
2025
Q2 		$576K Sell
38,900
-35,400
-48% -$587K ﹤0.01% 3266
2025
Q1 		$1.33M Sell
74,300
-33,500
-31% -$680K ﹤0.01% 2205
2024
Q4 		$1.88M Sell
107,800
-11,300
-9% -$200K ﹤0.01% 1976
2024
Q3 		$1.67M Buy
119,100
+62,500
+110% +$651K ﹤0.01% 1872
2024
Q2 		$465K Sell
56,600
-5,300
-9% -$35.7K ﹤0.01% 2629
2024
Q1 		$477K Buy
61,900
+9,400
+18% +$79.3K ﹤0.01% 2783
2023
Q4 		$472K Buy
52,500
+37,700
+255% +$274K ﹤0.01% 3127
2023
Q3 		$132K Sell
14,800
-16,000
-52% -$226K ﹤0.01% 4196
2023
Q2 		$473K Buy
30,800
+18,700
+155% +$340K ﹤0.01% 3085
2023
Q1 		$272K Buy
+12,100
New +$257K ﹤0.01% 3382
2022
Q3 		– Sell
-300
Closed -$7K – 8290
2022
Q2 		$7K Buy
300
+200
+200% +$5.03K ﹤0.01% 6957
2022
Q1 		$3K Sell
100
-12,500
-99% -$332K ﹤0.01% 7658
2021
Q4 		$391K Buy
12,600
+2,500
+25% +$70.4K ﹤0.01% 4404
2021
Q3 		$245K Buy
10,100
+9,500
+1,583% +$175K ﹤0.01% 4955
2021
Q2 		$9K Buy
600
+200
+50% +$3.94K ﹤0.01% 7574
2021
Q1 		$10K Buy
400
+300
+300% +$8.29K ﹤0.01% 7059
2020
Q4 		$3K Buy
+100
New +$2.33K ﹤0.01% 6185
2020
Q3 		– Sell
-13,000
Closed -$265K – 6563
2020
Q2 		$265K Buy
+13,000
New +$207K ﹤0.01% 3154
2020
Q1 		– Sell
-5,300
Closed -$75K – 5754
2019
Q4 		$75K Sell
5,300
-3,000
-36% -$38.3K ﹤0.01% 3813
2019
Q3 		$96K Sell
8,300
-42,600
-84% -$704K ﹤0.01% 3590
2019
Q2 		$1.02M Sell
50,900
-4,100
-7% -$81K 0.01% 1573
2019
Q1 		$1.25M Buy
55,000
+54,900
+54,900% +$1.21M 0.01% 1260
2018
Q4 		$23K Sell
100
-100
-50% -$2.49K ﹤0.01% 3980
2018
Q3 		$6K Buy
200
+100
+100% +$2.86K ﹤0.01% 4794
2018
Q2 		$3K Hold
100
– – ﹤0.01% 4905
2018
Q1 		$2K Hold
100
– – ﹤0.01% 4655
2017
Q4 		$2K Sell
100
-2,000
-95% -$45.7K ﹤0.01% 4695
2017
Q3 		$52K Buy
2,100
+2,000
+2,000% +$44K ﹤0.01% 3617
2017
Q2 		$2K Sell
100
-2,500
-96% -$45.3K ﹤0.01% 4589
2017
Q1 		$48K Sell
2,600
-200
-7% -$3.91K ﹤0.01% 3438
2016
Q4 		$53K Sell
2,800
-64,800
-96% -$1.33M ﹤0.01% 3233
2016
Q3 		$1.51M Sell
67,600
-14,800
-18% -$282K 0.02% 1000
2016
Q2 		$1.47M Sell
82,400
-142,000
-63% -$2.3M 0.02% 992
2016
Q1 		$3.06M Buy
224,400
+118,000
+111% +$1.79M 0.04% 559
2015
Q4 		$2.05M Buy
106,400
+52,900
+99% +$1.06M 0.02% 837
2015
Q3 		$1.08M Buy
53,500
+50,500
+1,683% +$1.5M 0.02% 1184
2015
Q2 		$99K Sell
3,000
-31,800
-91% -$871K ﹤0.01% 3099
2015
Q1 		$834K Buy
+34,800
New +$531K 0.01% 1225
2014
Q4 		– Sell
-9,300
Closed -$84K – 5282
2014
Q3 		$84K Sell
9,300
-20,900
-69% -$246K ﹤0.01% 3152
2014
Q2 		$355K Buy
+30,200
New +$409K 0.01% 1930

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading's TVTX Position: Q4 2025 in Review

Group One Trading sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 15,008 shares — an estimated $488K sold.

Group One Trading first reported a position in TVTX in Q2 2014 and held it in 28 quarters. The position peaked at $1.21M in Q1 2016. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Group One Trading reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 15,008 Travere Therapeutics shares in Q4 2025, an estimated $488K.
  • Group One Trading first reported a position in Travere Therapeutics in Q2 2014 and held it in 28 quarters.
  • Group One Trading's Travere Therapeutics position peaked at $1.21M in Q1 2016.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.